ADVITOS GmbH

ADVITOS developed the CE-marked and worldwide patented ADVOS technology (ADVanced Organ Support) – the only therapy worldwide offering multi organ support integrated in one single device. ADVOS improves survival of ICU patients by simultaneously supporting all three main detoxification organs: the liver, the lung and the kidney. The solution allows fluid-based elimination of: water-soluble toxins (kidney), protein-bound toxins (liver and kidney), and CO2 (lungs). In addition, ADVOS enables treatment of acid-base disbalances through patient individual correction of the blood pH value. The ADVOS therapy is used in intensive care units at 20 leading university hospitals throughout Germany and is on its way to penetrating the international market. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 880349 & 961745. Legal Notice: https://advitos.com/en/legal-notice/ Data Privacy: https://advitos.com/en/data-privacy/